歌禮制藥(1672.HK)大漲超20% 兩款藥物有望納入國家重大公共衞生應急審批通道
格隆匯1月29日丨歌禮制藥(1672.HK)今日股價快速走高,現漲20.13%,報3.58港元,最新總市值為39.61億港元。消息上,針對新型冠狀病毒感染的肺炎診療方案(試行第三版)推薦的兩款艾滋病病毒蛋白酶抑制劑,歌禮制藥旗下子公司歌禮公司已分別研發出國產仿製藥或療效更佳的創新藥,分別是國產首仿藥利托那韋片和1類創新藥艾滋病病毒蛋白酶抑制劑ASC09複方製劑片。在抗擊疫情的關鍵時刻,這兩款藥物有望納入國家重大公共衞生應急審批通道,快速獲批上市。1月22日,國家衞生健康委辦公廳、國家中醫藥管理局辦公室發佈關於印發新型冠狀病毒感染的肺炎診療方案(試行第三版)的通知,在目前尚無有效抗病毒藥物的情況下,洛匹那韋/利托那韋成為抗病毒治療的候選藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.